Motus GI makes the Pure-Vu System, a medical device that cleans the gastrointestinal tract during endoscopy procedures. The device attaches to standard colonoscopes and gastroscopes, using irrigation and suction to remove fecal matter, blood, and other debris during the procedure itself — rather than relying solely on pre-procedure bowel prep. The primary target market is inpatient colonoscopies, where inadequate bowel preparation is a persistent clinical problem, particularly among elderly or frail patients. Pure-Vu consists of a reusable workstation controller and a single-use disposable "Flex-Channel" that attaches to the endoscope. Motus GI sells directly to acute care hospitals in the U.S., targeting gastroenterologists and hospital administrators, and holds a sole-source designation from the Veterans Health Administration. The business model is a classic razor-and-blades structure: the workstation is placed at the hospital and the disposable Flex-Channel generates recurring revenue per procedure. Revenue scales with the number of workstations placed and the volume of procedures performed per site. A key constraint is the absence of dedicated reimbursement coverage — Medicare denied the company's application for new technology payments in 2021 — meaning hospitals bear the full incremental cost, limiting adoption. Motus GI's commercial and financial position is precarious: as of year-end 2023, the company had 15 employees and was conducting a formal strategic review exploring acquisition, merger, asset sale, or licensing, explicitly acknowledging that failure to complete a transaction could require bankruptcy or liquidation. The company's core asset is its Pure-Vu IP portfolio, with patents running at least until 2040.